241 related articles for article (PubMed ID: 19104519)
1. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.
Sanz G; Fuster V
Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):101-10. PubMed ID: 19104519
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the polypill concept and ongoing clinical trials.
Castellano JM; Sanz G; Fuster V
Can J Cardiol; 2014 May; 30(5):520-6. PubMed ID: 24786442
[TBL] [Abstract][Full Text] [Related]
3. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
[TBL] [Abstract][Full Text] [Related]
4. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
Bramlage P; Sims H; Minguet J; Ferrero C
Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
[TBL] [Abstract][Full Text] [Related]
5. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A; Kruger A; Kutty R; Lanas F; Lisheng L; Wei L; Lopez-Jaramillo P; Oguz A; Rahman O; Swidan H; Yusoff K; Zatonski W; Rosengren A; Teo KK;
Lancet; 2011 Oct; 378(9798):1231-43. PubMed ID: 21872920
[TBL] [Abstract][Full Text] [Related]
6. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
Naderi SH; Bestwick JP; Wald DS
Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
[TBL] [Abstract][Full Text] [Related]
7. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
[TBL] [Abstract][Full Text] [Related]
8. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Xavier D; Pais P; Sigamani A; Pogue J; Afzal R; Yusuf S;
Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):96-7. PubMed ID: 19104516
[No Abstract] [Full Text] [Related]
9. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
[TBL] [Abstract][Full Text] [Related]
10. Polypill and global cardiovascular health strategies.
Sanz G; Fuster V
Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
[TBL] [Abstract][Full Text] [Related]
11. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.
Cordero A; Rodriguez Padial L; Batalla A; López Barreiro L; Torres Calvo F; Castellano JM; Ruiz E; Bertomeu-Martínez V;
Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27957818
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy to prevent cardiovascular disease: slow progress.
Smith R; McCready T; Yusuf S
JAMA; 2013 Apr; 309(15):1595-6. PubMed ID: 23529576
[No Abstract] [Full Text] [Related]
13. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
Sanz G; Fuster V
Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
[TBL] [Abstract][Full Text] [Related]
14. Fixed drug combination in hypertension and hyperlipidaemia in the developing world.
Seedat YK
Cardiovasc J Afr; 2008; 19(3):124-6. PubMed ID: 18568170
[No Abstract] [Full Text] [Related]
15. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
16. Combined use of polypill components in patients with type 2 diabetes mellitus.
Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
[TBL] [Abstract][Full Text] [Related]
17. Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V; Escobar C
Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
[TBL] [Abstract][Full Text] [Related]
18. Polypill in cardiovascular disease: has it's time come?
Kuppuswamy V; Choo WK; Gupta S
Indian Heart J; 2009; 61(4):322-7. PubMed ID: 20635733
[No Abstract] [Full Text] [Related]
19. Polypill: quo vadis?
Muscente F; De Caterina R
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
[TBL] [Abstract][Full Text] [Related]
20. The cardiovascular polypill in high-risk patients.
Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]